We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.51%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.22B
AUM Growth
+$345M
Cap. Flow
-$140M
Cap. Flow %
-6.29%
Top 10 Hldgs %
38.04%
Holding
103
New
16
Increased
23
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$82.9M
2
MCK icon
McKesson
MCK
+$64.6M
3
GKOS icon
Glaukos
GKOS
+$62M
4
VTRS icon
Viatris
VTRS
+$60.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$34.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$68.6M
2
GILD icon
Gilead Sciences
GILD
+$66.4M
3
NXTM
NxStage Medical Inc.
NXTM
+$60.1M
4
NVRO
NEVRO CORP.
NVRO
+$28M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.21%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$187M
$2.42M 0.11%
117,647
– –
ITCI
77
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.86M 0.08%
+118,116
New +$1.73M
MDXG icon
78
MiMedx Group
MDXG
$640M
$1.78M 0.08%
+150,000
New +$2.22M
RARX
79
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.49M 0.07%
102,150
+19,557
+24% +$296K
BCRX icon
80
CALL
BioCryst Pharmaceuticals
BCRX
$2.34B
– –
-500,000
Closed -$2.78M
ELV icon
81
Elevance Health
ELV
$82.8B
– –
-75,182
Closed -$14.1M
EPIX
82
DELISTED
ESSA Pharma
EPIX
– –
-70,812
Closed -$779K
GILD icon
83
CALL
Gilead Sciences
GILD
$166B
– –
-750,000
Closed -$53.1M
GILD icon
84
Gilead Sciences
GILD
$166B
– –
-938,515
Closed -$66.4M
MNKD icon
85
MannKind Corp
MNKD
$1.24B
– –
-2,702,403
Closed -$3.81M
PBYI icon
86
PUT
Puma Biotechnology
PBYI
$424M
– –
-104,000
Closed -$9.09M
ZVRA icon
87
Zevra Therapeutics
ZVRA
$734M
– –
-44,038
Closed -$2.82M
NVRO
88
DELISTED
NEVRO CORP.
NVRO
– –
-376,308
Closed -$28M
KA
89
DELISTED
Kineta, Inc. Common Stock
KA
– –
-123
Closed -$81K
JNCE
90
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-247,872
Closed -$3.48M
AET
91
DELISTED
Aetna Inc
AET
– –
-130,000
Closed -$19.7M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2017 Portfolio in Review

As of Q3 2017, Deerfield Management held 103 positions worth $2.22B, up 18% from $1.87B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $140M in Q3 2017, closing 12 positions and reducing 25 holdings. Its most notable exit was Gilead Sciences, an estimated $66.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 72% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Insulet worth $27.4M.

  • Deerfield Management's largest Q3 2017 buy was Insulet: 497,000 shares worth $27.4M.
  • Deerfield Management added most to DexCom in Q3 2017, an estimated $82.9M increase.
  • Deerfield Management's biggest Q3 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $68.6M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2017, selling an estimated $66.4M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.22B portfolio in Q3 2017.
  • Deerfield Management opened 16 new positions and closed 12 in Q3 2017.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $2.22B.

Based on Deerfield Management's 13F filing for Q3 2017, filed 13 Nov 2017.